Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study

OBJECTIVE: To evaluate the efficacy of fremanezumab in patients with chronic migraine (CM) and moderate to severe depression. BACKGROUND: Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene–related peptide, has been approved for the preventive treatment of mi...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Headache
Главные авторы: Lipton, Richard B., Cohen, Joshua M., Galic, Maja, Seminerio, Michael J., Yeung, Paul P., Aycardi, Ernesto, Bigal, Marcelo E., Bibeau, Kristen, Buse, Dawn C.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2021
Предметы:
Research Submissions
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8251795/
https://ncbi.nlm.nih.gov/pubmed/33891348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.14097
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы